drugset / Trial / NCT00349219

TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer

NCT00349219

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare first-line erlotinib followed at progression by second-line chemotherapy vs. first-line chemotherapy followed at progression by second-line erlotinib in the treatment of Advanced Non Small Cell Lung Cancer (NSCLC).

Timeline

Start
2006-12
Primary completion
2011-12
Completion
2012-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cisplatin Other / unclassified 80 mg/m2
Comparator Erlotinib Small molecule 150 mg Oral
Comparator Gemcitabine Small molecule 1200 mg/m2